The shadow of generic competition has repeatedly loomed above copyright’s iconic drug, Sildenafil, sparking questions about the future of related drug holdings. While first periods saw impressive returns, the patent expiration has created the way for less expensive alternatives, possibly reducing profitability and creating a significant hazard fo